Advanced Malignant Solid Neoplasm clinical trials

Light therapy after radiation for inoperable airway tumors

This trial tests a new light-activated therapy (interstitial photodynamic therapy) after palliative radiation to shrink inoperable airway tumors and improve breathing. It is for people with solid cancers that block the airway from the outside and cannot be removed with surgery.

Testing a new drug for advanced solid tumors

This trial tests an experimental drug for people with advanced solid tumors, including small cell lung cancer, that have stopped responding to standard treatments. The goal is to find out if the drug is safe and effective.

Immune Cell Injection for Advanced Solid Tumors

This trial tests a new treatment where immune cells (called macrophage exosomes) are injected directly into your tumor to help your body fight the cancer. It's designed for advanced cancers that have not responded to standard treatments.

Combination therapy for advanced kidney cancer after first-line treatment

This trial tests a combination of two drugs (SLC-3010 and axitinib) versus axitinib alone for people with advanced clear cell kidney cancer that has progressed after initial treatment. It aims to see if the combination is safer and more effective.

Planning ahead for teens and young adults with advanced cancer

This study tests an educational tool to help young adults with advanced solid tumors or high-grade brain tumors think about and discuss their future healthcare wishes early. It may help you feel more prepared and in control of your care.

Testing a new combination of cancer drugs for HER2-positive tumors and breast cancer

This trial tests the safety of combining two drugs, CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd), in people with HER2-positive solid tumors or certain types of breast cancer. If you have advanced cancer that hasn't responded to other treatments, this study may be an option.

VB15010 for advanced solid tumors with HRR gene mutation

This trial tests an oral medication (VB15010) in people with advanced solid tumors that have a specific DNA repair gene mutation (called HRR mutation). The goal is to see if the drug can stop or slow down cancer growth.

Testing IAP0971 in advanced solid tumors and lung cancer

This trial tests a new drug called IAP0971 for people with advanced solid tumors or a specific type of lung cancer. It may help if your cancer has not responded to other treatments or if you have PD-L1-positive lung cancer that hasn't been treated yet.

Combination therapy for advanced solid tumors

This trial tests a combination of three drugs—axatilimab, retifanlimab, and paclitaxel—for people with advanced solid tumors that have spread. It aims to see if this combination can shrink tumors or slow their growth, and it is for people who have already tried taxane chemotherapy.

TAK-243 for advanced cancers that haven't responded to other treatments

This trial tests a new drug called TAK-243 for people with advanced cancers (solid tumors or lymphomas) that have not responded to other treatments. It aims to see if the drug is safe and how well it works.

Study of OR502 alone and with other cancer treatments

This trial tests an experimental drug called OR502, which targets a protein on immune cells, to see if it can help fight advanced solid tumors. It is given alone or with other anti-cancer drugs, and the study aims to find the best dose and see how well it works.

How PD-1 therapy affects immune cells in advanced cancers

This study looks at how your immune system responds to PD-1/PD-L1 immunotherapy (drugs like Keytruda or Opdivo) for advanced melanoma, lung cancer, and similar cancers. It involves regular blood tests to track your immune cells, which may help doctors understand why these treatments work for some people better than others.

NV-001 for advanced solid tumors after standard treatments

This trial tests a new drug called NV-001 for people with advanced solid tumors that are no longer responding to standard treatments. It aims to see if the drug is safe and can help shrink or slow tumor growth.

Study of an oral drug for solid tumors or glioblastoma

This trial tests an oral drug called NBM-BMX for people with advanced solid tumors that have not responded to other treatments, or for people with newly diagnosed glioblastoma (a type of brain cancer). The study aims to see if the drug is safe and effective.

Home cancer treatment vs clinic treatment for advanced cancer

This Phase 2 trial compares giving certain standard cancer infusions at home versus in a clinic. It may help people avoid clinic visits while still receiving the same cancer treatment safely.

PM8002 for advanced solid tumors that have stopped responding

This Phase 1/2 study tests PM8002 in people with advanced solid cancers to see if it can work and is safe. It may help if your cancer has measurable disease and you have not fully recovered from side effects of prior treatment.

Safety and drug test for AUR107 in advanced cancers

This early-phase study tests whether AUR107 is safe and may help shrink or control advanced solid tumors that have come back or progressed. You may be considered if standard treatments no longer work and you meet specific blood, organ, and health requirements.

Trastuzumab plus pertuzumab for HER2-mutated cancers

This trial tests whether combining trastuzumab and pertuzumab can treat cancers that have HER2 amplification or an activating HER2 mutation. It looks at people ages 12 and older, and may include both children/teens and adults, using the study drug based on their HER2 test results.

CPI-613 plus hydroxychloroquine with chemo for advanced solid tumors

This trial tests a drug called CPI-613 (devimistat) combined with hydroxychloroquine along with either 5-fluorouracil or gemcitabine chemo. It’s for people with advanced cancers that have stopped responding to standard treatments, aiming to shrink tumors and slow cancer growth.

A Study of PHST001 in Advanced Solid Tumors

Dabrafenib and trametinib for BRAF V600 cancers

This trial tests two targeted drugs (dabrafenib and trametinib) for patients whose cancer has a specific change in the BRAF gene called V600. These drugs work together to block signals that help the cancer grow. The trial is for children, teenagers, and adults with many types of cancer, except for a few common ones that already have approved treatments.

Testing Calderasib for advanced solid tumors with KRAS G12C mutation

This trial tests a new drug, Calderasib (MK-1084), for people with advanced solid tumors that have a specific KRAS G12C mutation and aren't getting better with standard treatments. The goal is to see if the drug can help shrink or control the cancer.

Testing TQB3142 in advanced tumors

This trial tests a new drug called TQB3142 in people with advanced cancers that have not responded to standard treatments. The goal is to find a safe dose and see how the drug works in the body.

Study of TGW101 for advanced solid tumors

This trial tests a new drug called TGW101 for people with certain advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and may help shrink tumors.